Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3284553 | 0.98 | LMNA (0.35) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL2547155 | 0.78 | TSHR (0.33) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL8947276 | 0.78 | TSHR (0.33) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL1930627 | 0.76 | TSHR (0.32) | LMNATSHR | |
| SCHEMBL6454576 | 0.76 | TSHR (0.32) | LMNATSHR | |
| SCHEMBL3382502 | 0.76 | TSHR (0.32) | LMNATSHR | |
| SCHEMBL28899300 | 0.74 | SLC22A2 (0.31) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL28399558 | 0.73 | TSHR (0.35) | TSHR | |
| SCHEMBL3382765 | 0.72 | LMNA (0.36) | LMNATSHR | |
| SCHEMBL3392844 | 0.72 | SLC22A2 (0.41) | LMNAGRIN1GRIN2ASLC22A1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190298662-A1 | TRANSDERMAL ADMINISTRATION OF MEMANTINE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2019-10-03 | — | — | US | disclosed |
| US-10363228-B2 | Transdermal administration of memantine | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2019-07-30 | — | — | US | disclosed |
| EP-2582364-B1 | TRANSDERMAL ADMINISTRATION OF MEMANTINE | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2019-05-01 | — | — | EP | disclosed |
| CN-107468673-A | Transdermal administration of memantine | LTS勒曼治疗系统股份公司 | 2017-12-15 | — | — | CN | disclosed |
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8796491-B2 | Process for manufacturing adamantane derivatives with high yield | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-08-05 | — | — | US | disclosed |
| EP-2582364-A2 | TRANSDERMAL ADMINISTRATION OF MEMANTINE | LTS LOHMANN Therapie-Systeme AG (DE) | 2013-04-24 | — | — | EP | disclosed |
| CN-103068377-A | Transdermal administration of memantine | LOHMANN THERAPIE SYST LTS | 2013-04-24 | — | — | CN | disclosed |
| WO-2011157416-A2 | TRANSDERMAL ADMINISTRATION OF MEMANTINE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2011-12-22 | — | — | WO | disclosed |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2331495-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | Merz Pharma GmbH & Co. KGaA (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010015415-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-02-11 | — | — | WO | disclosed |
| US-20080312587-A1 | System for the Oral Administration of Solids to Persons Suffering from Dementia | GRUENETHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080300390-A1 | REDUCING CARBOHYDRATE DERIVATIVES OF ADAMANTANE AMINES, AND SYNTHESIS AND METHODS OF USE THEREOF | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-12-04 | — | — | US | disclosed |
| EP-1893158-A1 | SYSTEM FOR THE ORAL ADMINISTRATION OF SOLIDS TO PERSONS SUFFERING FROM DEMENTIA | Grünenthal GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1836153-A2 | REDUCING CARBOHYDRATE DERIVATIVES OF ADAMANTANE AMINES, AND SYNTHESIS AND METHODS OF USE THEREOF | Forest Laboratories, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006131328-A1 | SYSTEM FOR THE ORAL ADMINISTRATION OF SOLIDS TO PERSONS SUFFERING FROM DEMENTIA | Grünenthal GmbH (DE) | 2006-12-14 | — | — | WO | disclosed |
| US-20060211650-A1 | Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof | FOREST LABORATORIES, INC. (US) | 2006-09-21 | — | — | US | disclosed |
| WO-2006066006-A2 | REDUCING CARBOHYDRATE DERIVATIVES OF ADAMANTANE AMINES, AND SYNTHESIS AND METHODS OF USE THEREOF | FOREST LABORATORIES, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211650-A1 | Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof | FUT5, FUT6, CHIT1 | LMNA 2465/4885GRIN1 1047/4885GRIN2A 1631/4885 |
| US-20080300390-A1 | REDUCING CARBOHYDRATE DERIVATIVES OF ADAMANTANE AMINES, AND SYNTHESIS AND METHODS OF USE THEREOF | FUT5, FUT6, CHIT1 | LMNA 2465/4885GRIN1 1047/4885GRIN2A 1631/4885 |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | BACE1, BACE2, APP | LMNA 3107/4885GRIN1 958/4885GRIN2A 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.